Kim A. Connelly

FRACP, PhD, MBBS

Scientist

Biography

Dr. Kim Connelly is a Cardiologist and Scientist who is both nationally recognized as an expert in echocardiography, cardiovascular MRI and the impact of diabetes upon cardiac function and ventricular remodeling. His work has been recognized evident by winning the “Young Investigator of the Year Award” by the Canadian Cardiovascular Society, an Early Researcher Award in 2014, and a CIHR New Investigator award in 2014.

Dr. Connelly runs a basic research laboratory at the Keenan Research Centre at St. Michael’s Hospital where he focuses upon basic mechanisms of disease – primarily around the role of pathological extracellular matrix accumulation and the pro-sclerotic cytokine transforming growth factor beta, with a focus upon translating discoveries into therapies in humans. He developed the first hemodynamically validated model of diabetes induced HFpEF. He is the Director of the Krembil Stem Cell Facility at St. Michael’s Hospital and uses regenerative cell based therapies to improve cardiac and renal dysfunction as a result of diabetes. He has research support from the HSF of Canada, CIHR and CFI along with significant research support from the pharmaceutical industry. His work has been published in journals such as the NEJM, Circulation, Journal of the American college of Cardiology, Circulation Research, Diabetes, Cell Metabolism and Lancet Endocrinology and Diabetes.

His H index is 45, and I index of 140.

Dr Connelly is immediate past president of the Canadian Society of Cardiac Magnetic resonance imaging. He runs a translational imaging laboratory and uses hyperpolarized C13 metabolic imaging to understand metabolism in the human heart in real time, as well as CMR to understand the impact of exercise upon cardiac remodeling. He was senior author of the EMPA HEART study along with Dr Verma and Zinman to assess the mechanism by which the SGLT2i empagliflozin provided cardiac protection in patients with type 2 DM. Finally, he was past section lead of 2018 macrovascular complications section for the Diabetes Canada Clinical practice updates and is current chair of the Canadian Cardiovascular Society guidelines.

Recent Publications

  1. Laurier, N, Salvini, Z, Syed, LD, Hodzic, A, Ni, J, Poirier, P et al.. Normal echocardiographic and electrocardiographic indices in young female athletes: A meta-analysis across sex, types of sports, races and ethnicities. Eur J Prev Cardiol. 2025; :. doi: 10.1093/eurjpc/zwaf755. PubMed PMID:41289042 .
  2. Leis, BT, Cote, M, Connors, WJ, Davierwala, PM, Brothers, TD, Morton, LM et al.. Management of Infective Endocarditis Secondary to Injection Drug Use: Practical Recommendations for Clinicians From a Canadian Working Group. Can J Cardiol. 2025; :. doi: 10.1016/j.cjca.2025.11.009. PubMed PMID:41276214 .
  3. Sedrak, P, Dounaevskaia, V, Mancini, GBJ, Zieroth, S, McKelvie, RS, Chiu, W et al.. Vaccination in Patients with Cardiovascular Disease: A Case-Based Approach and Contemporary Review. CJC Open. 2025;7 (10):1375-1388. doi: 10.1016/j.cjco.2025.09.004. PubMed PMID:41180339 PubMed Central PMC12572865.
  4. Lee, XA, Raschzok, S, Desjardins, JF, Van Loon, T, Plavetic, A, Kanny, O et al.. Left ventricular pressure-loading improves pressure-induced right ventricular remodeling by redistributing mechanical load and reducing mechanosignaling. Physiol Rep. 2025;13 (18):e70546. doi: 10.14814/phy2.70546. PubMed PMID:40969144 PubMed Central PMC12447007.
  5. Petrie, MC, Cherney, DZI, Desai, AS, Testani, JM, Verma, S, Chinnakondepalli, K et al.. Sodium zirconium cyclosilicate, hyperkalaemia, and spironolactone optimization in heart failure with reduced ejection fraction: The REALIZE-K open-label run-in phase. Eur J Heart Fail. 2025;27 (8):1491-1495. doi: 10.1002/ejhf.3787. PubMed PMID:40879354 PubMed Central PMC12482837.
  6. Rumman, RK, Verma, S, Chan, V, Fottinger, A, Quan, A, Hibino, M et al.. Comparison of myocardial mechanics after mitral valve repair with leaflet preservation versus leaflet resection: A subanalysis of the randomized Canadian Mitral Research Alliance CardioLink-2 trial. J Thorac Cardiovasc Surg. 2025; :. doi: 10.1016/j.jtcvs.2025.07.047. PubMed PMID:40783073 .
  7. Dauz, JD, Yazaki, K, Akazawa, Y, Meister, TA, Kabir, G, Kadowaki, S et al.. Dual inhibition of TGFβ and PDGF improves RV remodeling and function in response to RV pressure or volume-loading. Physiol Rep. 2025;13 (9):e70339. doi: 10.14814/phy2.70339. PubMed PMID:40323168 PubMed Central PMC12051373.
  8. Sedrak, P, Verma, R, Verma, M, Connelly, KA. Evolving Role of Double and Triple Therapy With GLP-1 Receptor Agonists in Obesity and Cardiovascular Disease. Can J Cardiol. 2025;41 (9):1809-1822. doi: 10.1016/j.cjca.2025.03.037. PubMed PMID:40311673 .
  9. Wu, E, Macklin, S, Zhang, Y, Thai, K, Nghiem, L, Di Ciano-Oliveira, C et al.. Induction of proximal tubular proliferation and lengthening in response to sodium glucose linked cotransporter-2 inhibition in experimental rats. J Diabetes Investig. 2025;16 (7):1232-1242. doi: 10.1111/jdi.70043. PubMed PMID:40260754 PubMed Central PMC12209515.
  10. Yerra, VG, Connelly, KA. MOTS-c: Magical Molecule for Diabetic Cardiomyopathy?. Cardiovasc Drugs Ther. 2025;39 (3):473-476. doi: 10.1007/s10557-025-07689-y. PubMed PMID:40172798 .
Search PubMed

Affiliations & Other Activities

  • Director, Krembil Stem Cell Facility, St. Michael’s Hospital
  • Staff Cardiologist, Division of Cardiology, St. Michael’s Hospital
  • Member, Richard Lewar Center, University of Toronto
  • Cardiologist, Division of Cardiology, Sunnybrook Health Sciences Centre